Geo-cultural Variation in MMSE Score Changes from Screening to Baseline in Alzheimer's Disease Trials
Wednesday, July 31 • 7:30 AM - 4:15 PM
MMSE and CDR Score Changes and Potential Score Inflation in Multinational Alzheimer's Disease Trials
Sunday, July 28 • 7:30 AM - 4:15 PM
Impact of Rater Change on MMSE Data: A Post-Hoc Analysis
Impact of Site Size on Data Quality in Early Alzheimer's Disease Clinical Trials
VISIT BOOTH 610
POSTER SESSIONS
RESOURCES
Central Ratings Services for CNS Research
Placebo Response Mitigation Services
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
Alzheimer's Trial Optimization Solutions
AAIC 2024 | Philadelphia, PA | July 28 - August 1
GUIDING YOUR ALZHEIMER'S TRIAL
TO SUCCESS
Meet the Signant Team at AAIC
Dawie Wessels Chief Medical Officer
Maria Kerwin Exec. Dir, Business Development
Sandra Marticio Sr. Dir, Business Development
Matthew Cordaro Dir, Business Development
Linda Berkowitz
Strategic Therapeutic Principal
Jennifer Betz
Sr. Dir, Business Development
David Miller
Clinical Vice President
Brian McAllister VP, Business Development
Alex Brooks
Strategic Alliance Director
Driving clinical assessment speed, simplicity and quality in Alzheimer’s and other neurological and CNS disorders
At Signant Health, we understand how good science is underpinned by great technology, and we continue to drive advancements in our solutions for Alzheimer’s disease research, and other CNS disorders. Our recent technology advancements have focused on three areas:
1. SITE-CENTRICITY
Clinical sites are the often-forgotten stakeholder in eClinical technology implementation, but through partnering with sites in user-focused research, we have advanced our solutions to drive easier participation for site users, including:
- ID Portal: A single place to access all solutions and tools associated with clinician ratings, through a single sign on.
- Clinical Profile and Rater Identification: Eliminating duplication across studies in rater onboarding activities to speed start-up activities.
2. ENDPOINT QUALITY
Accuracy, consistency and reliability underpin endpoint quality, essential for research in Alzheimer's disease and other CNS disorders. Our new developments help to drive high quality clinical evidence generation, and include:
- CDR System: Our new version is a modern, web-based solution with the same accuracy and reliability associated with the original CDR system.
- Blinded data analytics: We now provide real-time access to in-study data surveillance, refreshed daily, and supporting predictive analytics with machine learning, to drive endpoint quality throughout the study.
3. IMPLEMENTATION EFFICIENCY
Accelerating delivery timelines for start-up activities and mid-study design changes through:
- Rater Station: Faster implementation without hardware dependencies using our enhanced Rater Station solution.
- Marketplace: Simplifying integration with Rater Station and other solutions using our API marketplace allows direct data queries and seamless solution integrations.